Tetratherix Limited (ASX:TTX)

Australia · Delayed Price · Currency is AUD

5.80

-0.05 (-0.85%)

Nov 6, 2026, 4:10 PM AEDT

Market Cap	307.74M +39.0%
Revenue (ttm)	3.86M +266.9%
Net Income	-9.32M
EPS	-0.18
Shares Out	53.06M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,168
Open	5.51
Previous Close	5.85
Day's Range	5.50 - 5.85
52-Week Range	3.09 - 8.08
Beta	n/a
Analysts	Buy
Price Target	6.75 (+16.43%)
Est. Earnings	Nov 23, 2026

About Tetratherix

Tetratherix Limited engages in biomaterial and regenerative medicine business in Australia and internationally. The company manufactures and commercialize medical devices in the areas of bone regeneration, tissue spacing, tissue regeneration, and precision medicine applications through its Tetramatrix platform technology. Tetratherix Limited was incorporated in 2015 and is based in Alexandria, Australia. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2015

Employees 25

Stock Exchange Australian Securities Exchange

Ticker Symbol TTX

Full Company Profile

Financial Performance

In fiscal year 2026, Tetratherix's revenue was 3.86 million, an increase of 266.87% compared to the previous year's 1.05 million. Losses were -9.32 million, -1.11% less than in 2025.

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for TTX stock is "Buy." The 12-month stock price target is $6.75, which is an increase of 16.43% from the latest price.

Price Target

$6.75

(16.43% upside)

Analyst Consensus: Buy

Stock Forecasts